HANDOK Inc. (KRX:002390)
South Korea · Delayed Price · Currency is KRW 11,870
+100 (0.85%)
At close: Jul 30, 2025, 3:30 PM KST
HANDOK Revenue
HANDOK had revenue of 119.87B KRW in the quarter ending March 31, 2025, a decrease of -6.92%. This brings the company's revenue in the last twelve months to 498.45B, down -4.72% year-over-year. In the year 2024, HANDOK had annual revenue of 507.36B, down -2.94%.
Revenue (ttm)
498.45B
Revenue Growth
-4.72%
P/S Ratio
0.32
Revenue / Employee
524.69M
Employees
950
Market Cap
159.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 507.36B | -15.38B | -2.94% |
| Dec 31, 2023 | 522.74B | -21.02B | -3.87% |
| Dec 31, 2022 | 543.76B | 26.12B | 5.05% |
| Dec 31, 2021 | 517.64B | 14.03B | 2.79% |
| Dec 31, 2020 | 503.61B | 30.61B | 6.47% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| Peptron | 4.30B |
| HLB Co., Ltd. | 74.64B |
| PharmaResearch | 392.31B |